NCT00969254 (E01OSMPLS0108) is a Phase 3 clinical trial of Pílulas de Lussen in Dysuria, sponsored by Laboratorios Osorio de Moraes Ltda..

Who is sponsoring NCT00969254?

NCT00969254 is sponsored by Laboratorios Osorio de Moraes Ltda..

What drugs are being tested in NCT00969254?

Interventions in NCT00969254: Pílulas de Lussen, Pyridium®.

Is NCT00969254 still recruiting?

NCT00969254 is currently status unknown. Last updated 31 August 2009.

Last reviewed 2009-08-31 · How we verify

NCT00969254: E01OSMPLS0108

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase III Clinical Study, Prospective, Multicenter, Double-blind, Randomized, Double-dummy to Assess the Efficacy and Safety of "Pílulas de Lussen®" Compared to the Pyridium® in the Symptomatic Control of Dysuria

Status unknown Phase 3 Last updated 31 August 2009

What this trial tests

Phase 3 trial testing Pílulas de Lussen in Dysuria in 80 participants. Status unknown.

Timeline

1 December 2009

Primary endpoint
1 February 2010

1 March 2010

Quick facts

Lead sponsor	Laboratorios Osorio de Moraes Ltda.
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	80
Start date	1 December 2009
Primary completion	1 February 2010
Estimated completion	1 March 2010

Drugs / interventions tested

Pílulas de Lussen — full drug profile →
Pyridium®

Conditions studied

Dysuria — all drugs for Dysuria →

Sponsor

Laboratorios Osorio de Moraes Ltda. — full company profile →

Who can join

18 and older, any sex, with Dysuria. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Visual Analogic Scale and opinion of the investigator.
Time frame: 3 days

Sponsor's own description

Clinical Study, prospective, comparative, randomized, double-dummy entry with random from a total of 80 patients, 40 patients will receive the test medication (Pílulas de Lussen®) plus placebo and 40 patients will receive the comparative (Pyridium®) plus placebo.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00969254 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Laboratorios Osorio de Moraes Ltda.
Last refreshed: 31 August 2009

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00969254.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing